The efficacy and safety of imipenem/cilastatin in the treatment of severe bacterial infections.
We have assessed the efficacy and safety of imipenem/cilastatin in a non-comparative study of 27 immunocompromised patients suffering from severe bacterial infections. Moreover in two groups of 14 patients the efficacy of imipenem/cilastatin versus a standard broad spectrum antibiotic therapy has also been compared. Clinical and microbiological efficacy and side effects have been evaluated.
D'Amato
C
C
L. Spallanzani Hospital, Rome, Italy.
Armignacco
O
O
Antonucci
G
G
Bordi
E
E
Bove
G
G
De Carli
G
G
De Mori
P
P
Rosci
M A
MA
Visco
G
G
D000293:Adolescent; D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy*; D015377:Cilastatin / Q000009:adverse effects / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004697:Endocarditis, Bacterial / Q000188:drug therapy; D005260:Female; D006801:Humans; D015378:Imipenem / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000382:microbiology
D015377:Cilastatin; D015378:Imipenem